XML 46 R9.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Cash flows from operating activities:      
Net (loss) income $ (77,329) $ 7,028 $ (33,226)
Adjustments to reconcile net (loss) income to net cash used in operating activities:      
Depreciation and amortization 815 1,690 2,486
Remeasurement of acquisition-related contingent consideration 0 3,327 845
Remeasurement of financing-related contingent consideration 0 435 378
Amortization of debt discount and debt issuance costs 1,248 6,524 5,995
Changes in deferred tax (15,666) (7,431) (6,334)
Share-based compensation expense 8,872 2,999 519
Gain on sale of Hospital Products 0 (45,760) 0
Loss on deconsolidation of subsidiary 0 0 1,750
Gain from release of certain liabilities (217) (3,364) 0
Other adjustments 1,272 142 (254)
Net changes in assets and liabilities      
Accounts receivable 0 8,281 2,471
Inventories, net 0 (1,352) 1,155
Prepaid expenses and other current assets (439) 1,863 (1,187)
Research and development tax credit receivable 2,796 2,213 (1,014)
Accounts payable & other current liabilities 4,232 (2,788) 4,641
Deferred revenue 0 0 (114)
Accrued expenses 895 (13,226) 357
Earn-out payments for contingent consideration in excess of acquisition-date fair value 0 (5,323) (10,988)
Royalty payments for contingent consideration payable in excess of original fair value 0 (866) (1,748)
Other assets and liabilities (3,789) (3,126) (4,057)
Net cash used in operating activities (77,310) (48,734) (38,325)
Cash flows from investing activities:      
Purchases of property and equipment (26) (98) (29)
Proceeds from disposal of property and equipment 0 0 154
Proceeds from the disposition of the Hospital Products 16,500 25,500 0
Proceeds from sales of marketable securities 102,224 36,284 63,246
Purchases of marketable securities (61,769) (131,407) (24,648)
Net cash provided by (used in) investing activities 56,929 (69,721) 38,723
Cash flows from financing activities:      
Proceeds from the February 2020 private placement 0 60,570 0
Proceeds from the May 2020 public offering 0 116,924 0
Proceeds from issuance of ordinary shares 263 2,189 118
Other financing activities, net 0 0 (145)
Net cash provided by (used in) financing activities 263 179,683 (27)
Effect of foreign currency exchange rate changes on cash and cash equivalents (896) 720 78
Net change in cash and cash equivalents (21,014) 61,948 449
Cash and cash equivalents at January 1 71,722 9,774 9,325
Cash and cash equivalents at December 31 50,708 71,722 9,774
Supplemental disclosures of cash flow information:      
Income taxes paid (refund), net 76 (1,701) 140
Interest paid $ 6,469 $ 6,469 $ 6,469